loader
Please Wait
Applying Filters...
menu
    • menu

    Annual Sales of Eribulin reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

    Client Email Product
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Eribulin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 14,161,255Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 7Halaven

    PharmaCompass
    Left Arrow
    Right Arrow
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Halaven

    Eribulin

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Halaven

    Japan
    arrow
    Discovery on Target
    Not Confirmed

    Eisai

    Eribulin

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 359

    2019 Revenue in Millions : 385

    Growth (%) : -7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Halaven

    Eribulin

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Halaven

    Japan
    arrow
    Discovery on Target
    Not Confirmed

    Eisai

    Eribulin

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 331

    2020 Revenue in Millions : 344

    Growth (%) : 4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Halaven

    Eribulin

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Halaven

    Japan
    arrow
    Discovery on Target
    Not Confirmed

    Eisai

    Eribulin

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 316

    2021 Revenue in Millions : 331

    Growth (%) : -4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Halaven

    Eribulin Mesylate

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Halaven

    Japan
    arrow
    Discovery on Target
    Not Confirmed

    Eisai

    Eribulin Mesylate

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 260

    2022 Revenue in Millions : 316

    Growth (%) : -8

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Halaven

    Eribulin

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Halaven

    U.S.A
    arrow
    Luxepack
    Not Confirmed

    Eisai Co. Ltd.

    Eribulin

    Main Therapeutic Indication : Oncology

    Currency : USD

    2017 Revenue in Millions : 380

    2016 Revenue in Millions : 371

    Growth (%) : 3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Halaven

    Eribulin

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Halaven

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Eisai

    Eribulin

    Main Therapeutic Indication : Oncology

    Currency : USD

    2018 Revenue in Millions : 365

    2017 Revenue in Millions : 356

    Growth (%) : 2%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Halaven

    Eribulin

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Halaven

    Japan
    arrow
    Discovery on Target
    Not Confirmed

    Eisai

    Eribulin

    Main Therapeutic Indication : Oncology

    Currency : USD

    2019 Revenue in Millions : 378

    2018 Revenue in Millions : 377

    Growth (%) : 0

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF